Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status

Most clinical trials of non‐small‐cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a retrospective cohort to assess the potential clinical be...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Sci
Main Authors: Kano, Hirohisa, Ichihara, Eiki, Harada, Daijiro, Inoue, Koji, Kayatani, Hiroe, Hosokawa, Shinobu, Kishino, Daizo, Watanabe, Kazuhiko, Ochi, Nobuaki, Oda, Naohiro, Hara, Naofumi, Ninomiya, Kiichiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Clinical Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540975/
https://ncbi.nlm.nih.gov/pubmed/32726470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14590
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki